Pyrotinib in HER2-positive Early Breast Cancer

Summary

This is a Multi-cohort, Phase II Clinical Study of Neoadjuvant - Adjuvant Pyrotinib in the Treatment of HER2-positive Early Breast Cancer, To evaluate the efficacy and safety of the pyrotinib-containing study regimen in patients with early HER2-positive early breast cancer with neoadjuvant and postoperative different Residual tumor burden (RCB) scores.

Timeline

Start

2024-12-30

Primary completion

2027-12-30

Completion

2029-12-30

Drugs

Indications